Presbyopia - Pipeline Review, H1 2020

June 2020 | 60 pages | ID: P3DD9CDA6C0EN
Global Markets Direct

Abstracts

Presbyopia - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia - Pipeline Review, H1 2020, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape.
Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis and eye trauma.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Presbyopia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Presbyopia (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Presbyopia (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Presbyopia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 3, 3 and 2 respectively.
Presbyopia (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Presbyopia (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Presbyopia (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Presbyopia (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Presbyopia (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Presbyopia (Ophthalmology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Presbyopia (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Presbyopia (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Presbyopia - Overview
Presbyopia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Presbyopia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Presbyopia - Companies Involved in Therapeutics Development
Allergan Ltd
Cellix Bio Pvt Ltd
Eyenovia Inc
Kedalion Therapeutics Inc
Kubota Vision Inc
Novartis AG
Ocuphire Pharma Inc
Orasis Pharmaceuticals Ltd
Plex Pharmaceuticals Inc
Presbyopia Therapies LLC
Reven Pharmaceuticals Inc
ViewPoint Therapeutics Inc
Presbyopia - Drug Profiles
(aceclidine + tropicamide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diclofenac sodium + pilocarpine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(oxymetazoline hydrochloride + pilocarpine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(phentolamine mesylate + pilocarpine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGN-241622 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAP-1160 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLXOPH-561 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EV-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxymetazoline hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pilocarpine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPEC-1004A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Presbyopia and Cataract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Presbyopia - Dormant Projects
Presbyopia - Product Development Milestones
Featured News & Press Releases
Oct 10, 2019: Orasis Pharmaceuticals announces CSF-1 Eye Drop successfully met primary endpoint in phase 2b clinical study in Presbyopia
Mar 27, 2019: Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia
Nov 27, 2018: Orasis Announces Appointments of Richard L. Lindstrom, Eric D. Donnenfeld, and John Berdahl to its Scientific Advisory Board
Aug 02, 2018: Eye drop improves near vision in presbyopia patients
May 05, 2016: Encore Vision Announces Successful Phase I-II Study of Topical EV06 for the Treatment of Presbyopia
May 02, 2016: Encore Vision Announces Positive Results from the Phase I-II Study of Topical EV06 for the Treatment of Presbyopia
Jan 25, 2016: Encore Vision Announces Completion of Target Enrollment
Oct 05, 2015: Encore Vision Announces First Subject Enrolled in Study of Topical Treatment for Presbyopia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Presbyopia, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Presbyopia - Pipeline by Allergan Ltd, H1 2020
Presbyopia - Pipeline by Cellix Bio Pvt Ltd, H1 2020
Presbyopia - Pipeline by Eyenovia Inc, H1 2020
Presbyopia - Pipeline by Kedalion Therapeutics Inc, H1 2020
Presbyopia - Pipeline by Kubota Vision Inc, H1 2020
Presbyopia - Pipeline by Novartis AG, H1 2020
Presbyopia - Pipeline by Ocuphire Pharma Inc, H1 2020
Presbyopia - Pipeline by Orasis Pharmaceuticals Ltd, H1 2020
Presbyopia - Pipeline by Plex Pharmaceuticals Inc, H1 2020
Presbyopia - Pipeline by Presbyopia Therapies LLC, H1 2020
Presbyopia - Pipeline by Reven Pharmaceuticals Inc, H1 2020
Presbyopia - Pipeline by ViewPoint Therapeutics Inc, H1 2020
Presbyopia - Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Presbyopia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Allergan Ltd
Cellix Bio Pvt Ltd
Eyenovia Inc
Kedalion Therapeutics Inc
Kubota Vision Inc
Novartis AG
Ocuphire Pharma Inc
Orasis Pharmaceuticals Ltd
Plex Pharmaceuticals Inc
Presbyopia Therapies LLC
Reven Pharmaceuticals Inc
ViewPoint Therapeutics Inc